MJA insight - What's shaping medicine now

Terms and conditions

A) Terms and conditions for using this website

B) Providing feedback on this site

C) Privacy policy and copyright

 

Last updated: 1 June, 2010

 

A) Terms and conditions for using this website

InSight is a website owned by the Australasian Medical Publishing Company Proprietary Limited (AMPCo Pty Ltd), a private limited company, incorporated in Australia, ABN 20 000 005 854. The registered office is situated at AMPCo House, 277 Clarence Street, Sydney NSW 2000.

1. Use of this website

Please read the following website terms and conditions, which relate to information regarding general use of our website. By using this website, you are agreeing to these terms and conditions. From time to time we may change these terms and conditions, and will post revisions on our website. We recommend that you read these terms and conditions regularly.

2. Access to InSight

We try to ensure that website availability is uninterrupted and that transmissions will be error-free. However, we cannot, due to the nature of the internet, guarantee that your access will not be suspended or restricted from time to time including to allow for repairs, maintenance or the introduction of new facilities or services. We will of course try to limit the frequency and duration of any suspension or restriction. InSight can be accessed for free and such access is at our discretion and may be changed without notice.

3. Accounts and passwords

As a registered user of InSight, the details which are registered with us allow you, and only you, to use InSight for as long as we allow access. Personal accounts therefore may not be shared.

4. Intellectual property rights

The content, layout, design, data and graphics on this website are protected by Australian and other international copyright laws. Other than downloading a small proportion of content, strictly for your personal non-commercial use, or where this amounts to “fair dealing”, no part of the website may be reproduced, stored in a retrieval system or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording and/or otherwise) without our prior written consent. Any authorised uses of content must include the customary bibliographic citation, including author attribution, date, article, article title and the URL http://www.mjainsight.com.au and must include the copyright notices.

The AMPCo Pty Ltd trademarks and logos which are displayed on the website are the trademarks of AMPCo Pty Ltd and its licensors. Any use, including framing, metatags or other text utilising AMPCo Pty Ltd’s trademarks or other trademarks displayed, is strictly prohibited without our (or our Licensor’s) express written consent.

5. Permission for use of our intellectual property

Any request for permission to use our content or images, or other use of our intellectual property, should be made in writing to AMPCo.

6. Links

6.1 Other websites are welcome to link to pages in the InSight eNewsletter and Website provided that no attempt is made to pass off the content of the InSight eNewsletter and Website as the property of the linking website. We do not approve of websites presenting InSight eNewsletter and Website content as a frame within their web pages.

6.2 We do not grant permission for anyone to copy InSight eNewsletter and Website content to their own web pages.

7. Browsers

If you are using one of the popular “offline browsers” that allow you to download content from a site and read it later, please be aware that this amounts to only a small proportion of content and is strictly for your personal non-commercial use.

8. Your conduct

You must not use the website in any way that causes or is likely to cause the website or access to it to be interrupted, damaged or impaired in any way. You understand that you are solely responsible for all electronic communications and contents sent from your computer to us. You must use the website for lawful purposes only. You must not use the website for any of the following:

a. Fraudulent purposes in connection with a criminal offence or otherwise unlawful activity.

b.To send, use or re-use any material that is illegal, offensive, abusive, indecent, defamatory, obscene or menacing; or in breach of copyright, trademark, confidence, privacy or any other right; or is otherwise injurious to third parties; or objectionable; or which consists of or contains software viruses, political campaigning, commercial solicitation, chain letters, mass mailings or any spam.

c.To cause annoyance, inconvenience or needless anxiety.

9. Governing law

These terms and conditions shall be governed and construed in accordance with Australian laws, whose courts shall have exclusive jurisdiction.

Go to Page 2.

 


Jane McCredie: When religion and medicine collide
Should a religious organisation run health care facilities if its views impact on accepted community and...FULL STORY.

New study highlights medicine’s big earners
Men, radiologists and orthopaedic surgeons are the big winners while women and GPs are stuck at the bottom of...FULL STORY.

Karen Charlton: The costly skeleton in hospital closets...
Nutrition screening is recommended to identify malnutrition in older Australians but who is responsible for...FULL STORY.

Sandra Leggat: Empowering health managers
Many thanks for your comments. I wanted to respond to Dr De Leacy. Often management is accused of being an art, with no science. But here is...

Jane McCredie: Life in the app lane
Couldn't agree more, Jane. In an increasingly self-obsessed and risk-averse society, we are being flooded with information but deprived of...

Sandra Leggat: Empowering health managers
In my experience, the problem is far worse than merely having untrained managers. As Dr Ieraci points out, while clinicians are subject to...

Mental health funding lacks transparency
A review of government-funded mental health programs reveals little evidence of improved health outcomes …

More partners increases oral HPV risk
A new study shows that men have a significantly higher prevalence of oral HPV than women …

Evidence mounts for bevacizumab in breast cancer
While two new trials have shown benefit from adding bevacizumab to breast cancer treatments, further evidence is needed …

 

Copyright © 2012 AMPCo
Australasian Medical Publishing Company